Om denne podcast
Innovation to Impact is a podcast on decision-grade drug development in regulated environments.
We examine how high-stakes go/no-go calls are made inside pharma and biotech, and what evidence is required for new tools to change those decisions without creating hidden risk.
Each episode focuses on predictivity, translational risk, decision rights, and accountability (what breaks, who owns it, and what triggers a stop).
This is not a podcast about technology trends. It is about disciplined innovation that can survive audit, scale, and real-world biology.
Episoder
- The Danger of Data You Can’t Interpret · 35 min. · Sæson 2 Episode 3More data sounds good until it starts making everyone anxious, confused, or falsely confident. In this conversation, Brian Berridge, Nick Kelley, and Szczepan Baran explore how…
- De-Risking What Matters · 37 min. · Sæson 2 Episode 2In this episode of Innovation to Impact: Ruminations & Ramblings, Szczepan Baran, Brian Berridge, and Nick Kelley tackle one of the biggest problems in modern drug development…
- Innovation That Earns Deletion (Subtractive Trust) · 33 min. · Sæson 2 Episode 1Click here to watch a video of this episode. Drug development workflows only get heavier, and subtractive change requires predictivity and decision-grade evidence that can…
- Biology, Loops, and Decision-Grade Trust · 29 min. · Sæson 1 Episode 4Click here to watch a video of this episode. In drug development, go/no-go decisions concentrate translational risk and expose real consequences. When AI or digital biomarkers…
- Rethinking Return in Drug Development · 30 min. · Sæson 1 Episode 3Click here to watch a video of this episode. In drug development, ROI debates can drown out decision-grade evidence and the hard work of translational science. This episode asks…
- Predictivity Is the New Currency of Drug Development · 23 min. · Sæson 1 Episode 2Click here to watch a video of this episode. Drug development punishes optimism, and predictivity is one of the few defenses we have against translational risk. In this episode…
- Patients First. Platforms Second · 36 min. · Sæson 1 Episode 1Click here to watch a video of this episode. In drug development, translational science can generate endless options, but decision-grade evidence starts with the patient…








